The Antidote Collective of the American Academy of Clinical Toxicology (AACT) was formed in 2023 to address shortages associated with various antidotes and medications that impact the management of patients who present with toxicologic emergencies.
One goal of the Antidote Collective is to create channels of communications to various stakeholders to emphasize the importance of continued manufacturing of these agents. Another goal is the creation of consensus expert guidelines related to alternative treatment modalities for specific antidotes and medications that are currently on shortage, specifically physostigmine, dimercaprol (BAL), succimer, and edetate calcium disodium (CaNaEDTA).
Should AACT members have any questions, or concerns, please contact the Chair of the collective, Nadia Awad, PharmD, MS, BCPS, BCPPS, FAACT (nadia.i.awad@gmail.com).